Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics

Biochemical Pharmacology

Volumn 83, Issue 6, 2012, Pages 741-746

  Yang, Zhengguan ^a   Waldman, Alan S ^a   Wyatt, Michael D ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Etoposide; Homologous recombination; RAD51; Replication protein A; Thymidylate synthase

Indexed keywords

CAFFEINE; ENDONUCLEASE; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; MUTANT PROTEIN; RAD51 PROTEIN; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOTHERAPY; CONTROLLED STUDY; DNA STRAND BREAKAGE; FRAMESHIFT MUTATION; GENE DELETION; HELA CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENETIC VECTORS; HELA CELLS; HT29 CELLS; HUMANS; MUTATION; PHOSPHORYLATION; PROTEIN KINASES; RAD51 RECOMBINASE; RECOMBINATIONAL DNA REPAIR; REPLICATION PROTEIN A; THYMIDYLATE SYNTHASE; TOPOISOMERASE II INHIBITORS;

EID: 84862803522     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.12.022     Document Type: Article

References (37)

1. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917 (Pubitemid 40559005)
2. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921 (Pubitemid 40559006)
3. L.T. Hansen, C. Lundin, M. Spang-Thomsen, L.N. Petersen, and T. Helleday The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer Int J Cancer 105 2003 472 479 (Pubitemid 36578549)
4. H.L. Klein The consequences of Rad51 overexpression for normal and tumor cells DNA Repair (Amst) 7 2008 686 693
5. I. Schonn, J. Hennesen, and D.C. Dartsch Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage Apoptosis 16 2011 359 369
6. A. Slupianek, C. Schmutte, G. Tombline, M. Nieborowska-Skorska, G. Hoser, and M.O. Nowicki BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance Mol Cell 8 2001 795 806 (Pubitemid 33030213)
7. S.H. Berger, D.L. Pittman, and M.D. Wyatt Uracil in DNA: consequences for carcinogenesis and chemotherapy Biochem Pharmacol 67 2008 697 706
8. Z. Yang, A.S. Waldman, and M.D. Wyatt DNA damage and homologous recombination signaling induced by thymidylate deprivation Biochem Pharmacol 76 2008 987 996
9. J.C. Ko, Y.J. Su, S.T. Lin, J.Y. Jhan, S.C. Ciou, and C.M. Cheng Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells Biochem Pharmacol 79 2011 655 664
10. J.C. Ko, M.S. Tsai, Y.H. Kuo, Y.F. Chiu, S.H. Weng, and Y.C. Su Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine Biochem Pharmacol 81 2011 680 690
11. B.C. Waldman, Y. Wang, K. Kilaru, Z. Yang, A. Bhasin, and M.D. Wyatt Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase DNA Repair 7 2008 1624 1635
12. L.A. Parsels, J.D. Parsels, D.C. Tai, D.J. Coughlin, and J. Maybaum 5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells Cancer Res 64 2004 6588 6594 (Pubitemid 39297918)
13. H.M. Robinson, R. Jones, M. Walker, G. Zachos, R. Brown, and J. Cassidy Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil Oncogene 25 2006 5359 5369 (Pubitemid 44330279)
14. D. Wilsker, and F. Bunz Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival Mol Cancer Ther 6 2007 1406 1413 (Pubitemid 46712004)
15. Z. Xiao, J. Xue, T.J. Sowin, and H. Zhang Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy Mol Cancer Ther 5 2006 1935 1943 (Pubitemid 44336564)
16. C.S. Sorensen, L.T. Hansen, J. Dziegielewski, R.G. Syljuasen, C. Lundin, and J. Bartek The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair Nat Cell Biol 7 2005 195 201 (Pubitemid 40268135)
17. S.K. Binz, A.M. Sheehan, and M.S. Wold Replication protein A phosphorylation and the cellular response to DNA damage DNA Repair (Amst) 3 2004 1015 1024 (Pubitemid 39004091)
18. J.S. Liu, S.R. Kuo, and T. Melendy Phosphorylation of replication protein A by S-phase checkpoint kinases DNA Repair (Amst) 5 2006 369 380 (Pubitemid 43250664)
19. K.M. Sleeth, C.S. Sorensen, N. Issaeva, J. Dziegielewski, J. Bartek, and T. Helleday RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells J Mol Biol 373 2007 38 47 (Pubitemid 47390721)
20. J.M. Carethers, D.P. Chauhan, D. Fink, S. Nebel, R.S. Bresalier, and S.B. Howell Mismatch repair proficiency and in vitro response to 5-fluorouracil Gastroenterology 117 1999 123 131 (Pubitemid 29297628)
21. M. Meyers, M.W. Wagner, A. Mazurek, C. Schmutte, R. Fishel, and D.A. Boothman DNA mismatch repair-dependent response to fluoropyrimidine-generated damage J Biol Chem 280 2005 5516 5526 (Pubitemid 40280029)
22. D.J. Sargent, S. Marsoni, G. Monges, S.N. Thibodeau, R. Labianca, and S.R. Hamilton Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J Clin Oncol 28 2010 3219 3226
23. J. Wray, J. Liu, J.A. Nickoloff, and Z. Shen Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress Cancer Res 68 2008 2699 2707 (Pubitemid 351556267)
24. L. Li, S.H. Berger, and M.D. Wyatt Involvement of base excision repair in response to therapy targeted at thymidylate synthase Mol Cancer Ther 3 2004 747 753 (Pubitemid 39193756)
25. L. Li, E.E. Connor, S.H. Berger, and M.D. Wyatt Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency Biochem Pharmacol 70 2005 1458 1468 (Pubitemid 41483456)
26. Y. Luo, M. Walla, and M.D. Wyatt Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase DNA Repair (Amst) 7 2008 162 169
27. A.J. Pierce, R.D. Johnson, L.H. Thompson, and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells Genes Dev 13 1999 2633 2638 (Pubitemid 29508550)
28. T. Kanda, K.F. Sullivan, and G.M. Wahl Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells Curr Biol 8 1998 377 385 (Pubitemid 28173996)
29. D. Cortez Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases J Biol Chem 278 2003 37139 37145 (Pubitemid 37175228)
30. R.G. Syljuasen, C.S. Sorensen, L.T. Hansen, K. Fugger, C. Lundin, and F. Johansson Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage Mol Cell Biol 25 2005 3553 3562 (Pubitemid 40559562)
31. J.L. Grem, K.D. Danenberg, V. Kao, P.V. Danenberg, and D. Nguyen Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells Anticancer Drugs 13 2002 259 270 (Pubitemid 34492708)
32. C.T. Hsueh, D. Kelsen, and G.K. Schwartz UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner Clin Cancer Res 4 1998 2201 2206 (Pubitemid 28415668)
33. P.C. Fong, T.A. Yap, D.S. Boss, C.P. Carden, M. Mergui-Roelvink, and C. Gourley Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
34. C.J. Lord, and A. Ashworth Targeted therapy for cancer using PARP inhibitors Curr Opin Pharmacol 8 2008 363 369
35. J. O'Shaughnessy, C. Osborne, J.E. Pippen, M. Yoffe, D. Patt, and C. Rocha Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
36. F. Huang, N.A. Motlekar, C.M. Burgwin, A.D. Napper, S.L. Diamond, and A.V. Mazin Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening ACS Chem Biol 6 2011 628 635
37. S.L. Edwards, R. Brough, C.J. Lord, R. Natrajan, R. Vatcheva, and D.A. Levine Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115 (Pubitemid 351317441)